Acasti Pharma Cmn A (ACST) 1.89 $ACST Acasti Pharma

New Post Public Reply Private Reply Replies (0) Message Board

Sep 24, 2016 at 9:00 AM

Acasti Pharma Cmn A (ACST) 1.89 $ACST

Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data
Marketwire Canada - Wed Sep 14, 7:02AM CDT
Results Support Streamlined Regulatory Pathway for Novel Hypertriglyceridemia Drug
ACST: 1.89 (+0.01), NTB.TO: 1.39 (+0.07), NEPT: 1.05 (+0.05), APO.VN: 2.550 (+0.140)

Acasti Announces Grant of Stock Options
Marketwire Canada - Mon May 30, 7:01AM CDT
LAVAL, QUEBEC--(Marketwired - May 30, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation"

(NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces the issuance of fifty thousand class A common shares as part of a settlement agreement executed on February 5, 2016.
ACST: 1.89 (+0.01), APO.VN: 2.550 (+0.140)

Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13), GSK: 43.42 (-0.16), AGN: 243.94 (+0.51), ABUS: 3.96 (+0.01), ACST: 1.89 (+0.01), AZN: 33.97 (-0.31), CBAY: 1.95 (+0.03)

Acasti incurs Q3 net loss of CAD2.191m
M2 - Wed Jan 13, 6:07AM CST
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) stated on Tuesday that it recorded a net loss of CAD2.191m for the third quarter ended 30 November 2015.
ACST: 1.89 (+0.01)

Acasti reports 3Q loss
Automated Insights - Tue Jan 12, 5:24PM CST
LAVAL, Quebec (AP) _ Acasti Pharma Inc. (ACST) on Tuesday reported a fiscal third-quarter loss of $1.7 million, after reporting a profit in the same period a year earlier.
ACST: 1.89 (+0.01)

Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 12, 4:26PM CST
-- Important progress made with FDA on CaPre(R) development pathway
ACST: 1.89 (+0.01), APO.VN: 2.550 (+0.140)

Acasti Provides Update on CaPre(R) Development Pathway
GlobeNewswire - Wed Dec 16, 6:50AM CST
-- Encouraging response from FDA on CaPre(R) clinical development
ACST: 1.89 (+0.01), APO.VN: 2.550 (+0.140)

Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico
GlobeNewswire - Tue Dec 01, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"

(NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that the Japanese, Taiwanese and Mexican patent offices have each recently granted Acasti a composition and use patent (the "Patents"

.
ACST: 1.89 (+0.01), APO.VN: 2.550 (+0.140)

TSX Venture Exchange Daily Bulletins
CNW Group - Wed Oct 14, 5:14PM CDT
TSX VENTURE COMPANIES
ACST: 1.89 (+0.01)

Acasti Announces Second Quarter Results
GlobeNewswire - Wed Oct 14, 4:10PM CDT
-- Important progress made in FDA discussions on development pathway for CaPre(R)
ACST: 1.89 (+0.01), APO.VN: 2.550 (+0.140)

Acasti approves one for ten reverse stock split
M2 - Wed Sep 30, 5:23AM CDT
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) declared on Tuesday that it will consolidate its issued and outstanding Class A common shares on the ratio of one post-consolidation common share for every ten pre-consolidation common shares provided each fractional common share shall be rounded up.
ACST: 1.89 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

K-Jeonnam Gim Debuts on Amazon: Korean Seaweed Arrives

Korean Seaweed Ventures to the US Market Alright, folks, here's a twist for your snack drawer—Korean seaweed making waves right on Amazon's virtual shelves! Shinan 1004 Seaweed Co. is shaking things up with their brand spankin' new K-Jeonnam Gim. This ain't just any old sea greens we're talking about. We're dealing with crispy, roasted sheets bursting with savory, nutty...

Surfshark's No-Logs Policy Gets KPMG Backing

By Addison Perry Updated Nov 13, 2026 Category News Views 168

Surfshark's Commitment to Privacy Pardon my grizzled voice, but in today's world, where digital privacy often feels like a myth, having a VPN that sticks to its guns about not keeping logs is rare enough to make you look twice. Well, here comes Surfshark, loudly touting yet another seal of approval from one of the Big Four—KPMG. Not the first time for these folks, but...

Finding the Right Auto Insurance: What to Consider

Understanding the Basics of Auto Insurance Coverage Now, you might think the state knows best when it sets those minimum auto insurance requirements. But let's not kid ourselves—skimping on coverage can leave you high and dry if things go south on the road. That's where an expert voice like Corey Frazer's comes in, laying out why those limits often fall short. Minimum...

Schools Reimagine Yearbooks with Interactive Archives

Revamping School Memories for the Tech Age In a world where every facet of life is digitally chronicled, it's about time schools got on board the archival train in a dynamic way. That's where Rocket Alumni Solutions steps in, breathing fresh life into those dust-gathering yearbooks and sepia-toned photos. Tackling History Collection by Collection Think you can throw a...

Nonprofit and Partners Gift Homes to Veterans

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

$10,000 Boost Fuels Nichols College's Archaeological Quest

Webster First's Generous Contribution It's not every day you see a credit union digging into history—literally. Webster First Federal Credit Union just dropped ten grand to fuel Nichols College's archaeological adventures. This isn't some trivial check to post on Instagram. No, we're talking about funding some serious ground-penetrating radar (GPR) gadgetry that's set...

Noël Jolié's Cream Earns Spot on Oprah's List

The Powerhouse of Oprah's Seal of Approval Ever notice what happens when Oprah drops a nod towards any brand? It's like Midas touching everything gold. That's exactly the scenario with Noël Jolié, a Chicago-based luxury body care operation, hitting the jackpot by landing its Velours Silken Body Cream on Oprah's Favorite Things 2026. You can't buy this kind of press,...

BULL Faces Class Action After Regulatory Fines

Webull's Financial Quake Shakes Investors You don't expect to wake up to news of a stock in freefall, but here we are with Webull (NASDAQ:BULL) cratering after some rough compliance problems came to light. On November 5, 2026, Webull's stock tumbled nearly 11% thanks to FINRA slapping them with a $4.2 million fine for failing to keep their anti-money laundering (AML) and...

Windward Bio Surges 68% in Nasdaq Debut

By Ryan Hughes Updated Nov 13, 2026 Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Innovative Rotating Kitchen Organizer Up for Licensing

Dusting Off the Corners: A Fresh Spin on Kitchen Storage Just when you think there's nothing new under the sun when it comes to storing your kitchen gadgets, here comes an invention straight out of Billings, Montana. It's called The Rotating Kitchen Organizer, a nifty contraption that's all set to turn those dead corners into prime real estate. How many times have we...